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High dose rate brachytherapy before external beam irradiation in
inoperable oesophageal cancer
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Departments of'Gastroenterology and 2Radiotherapy, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Amsterdam, The
Netherlands.
Summary To induce fast relief of dysphagia in patients with oesophageal cancer high dose rate (HDR)
brachytherapy was applied before external radiotherapy in a prospective study. Seventy-four patients with
inoperable oesophageal cancer (36 squamous cell, 38 adenocarcinoma) were treated with a combination of
10 Gy HDR brachytherapy, followed by 40 Gy in 4 weeks external beam radiotherapy (EBRT), starting 2
weeks later. Tumour response, as measured by endoscopy and/or barium swallow, revealed complete remission
in 21 and partial response in 38 patients (overall response rate 80%). Improvement of dysphagia was induced
by brachytherapy within a few days in 39%, and achieved at the end of treatment in 70% of patients. Further
weight loss was prevented in 39 of the 59 patients who presented with weight loss. Pain at presentation
improved in 12 out of 25 patients. Median survival was 9 months. No differences in either response rate or
survival were found in squamous cell or adenocarcinoma. Side-effects were either acute with minimal
discomfort in 32 (42%) or late with painful ulceration in five patients (7%), occurring after a median of 4
months. A fistula developed in six patients, all with concurrent tumour. In conclusion, brachytherapy before
EBRT was a safe and effective procedure to induce rapid relief of dysphagia, especially when combined with
EBRT.
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The prognosis of oesophageal cancer is usually dismal.
Surgery is potentially curative in only a small subset of
patients (Altorki and Skinner, 1990). Oesophageal resection is
considered major surgery, which includes substantial
morbidity and mortality. Although post-operative mortality
has decreased over the last years and is acceptably low (5%)
in some centres, resection as a palliative measure is not
widely accepted in clinical practice. In the case of
unresectable oesophageal cancer or advanced locoregional
disease, radical radiotherapy may offer adequate palliation
(Beatty et al., 1979), although overall prognosis is poor and
progression may be apparent even during irradiation in up to
20% of patients (Wara et al., 1976). Since the review of the
literature (1954- 1979) on the role of radiotherapy by Earlam
and Cunho-Melo (1980), radiation techniques have changed,
especially after brachytherapy was in favour again when
remote control techniques became available, as described by
Rowland and Pagliero (1985); followed by others (Petrovich
et al., 1991; Smalley et al., 1994). In most studies (Caspers et
al., 1993; Flores et al., 1989; Gaspar, 1994; Hishikawa et al.,
1991; Hyden et al., 1988; Sur et al., 1992), intracavitary
irradiation has been used as a booster following external
radiotherapy, which has the advantage of delivering a high
dose to a small tumour volume.
As dysphagia is the main symptom in oesophageal cancer
leading to weight loss and deterioration of the general
condition, we applied brachytherapy before EBRT to induce
rapid tumour reduction and subsequent relief of dysphagia.
Aiming at optimal tumour regression and improved quality
of life, at the cost of minimal side-effects, we based our
regimen on the two largest series in the literature: that of
Flores et al. (1989), who combined a short course of EBRT
(40 Gy over 3 weeks) with medium dose rate brachytherapy
(15 Gy), and the wide experience of Hishikawa et al. (1991)
using high dose rate (2 x 6 Gy) in addition to EBRT (60 Gy
over 6 weeks). With regard to dysphagia and the generally
short life expectancy, we applied 10 Gy HDR brachytherapy
before a short duration radiotherapy scheme, 40 Gy over 3
weeks EBRT. When this appeared to be too toxic in a pilot
study, in nine out of 15 patients severe late side-effects, e.g.
ulceration, necrosis and fistula formation (Taal et al., 1996),
we adapted the regimen by giving the same EBRT dose over
4 weeks. In comparison, in the past, when brachytherapy was
not yet available, we applied a 6 week scheme of EBRT only:
40 Gy over 4 weeks plus 20 Gy over 2 weeks as a booster
dose to a smaller volume.
In this paper we report on response and side-effects of our
new scheme with upfront brachytherapy in a prospective
phase II trial.
Materials and methods
Patients
Between February 1991 and September 1994, 74 consecutive
patients with advanced inoperable oesophageal cancer
entered a prospective study of radiotherapy at the Nether-
lands Cancer Institute approved by the local medical ethics
committee. All patients, including those from the referring
hospitals, underwent a diagnostic endoscopy in our institute
and were discussed by the gastroenterologist and radiation
oncologist. The diagnosis was based on endoscopic biopsies.
Routine staging procedures consisted of physical examina-
tion, laboratory tests (haematology and blood chemistry),
chest radiograph, a barium swallow, endoscopy, compu-
terised tomography (CT) scan of the mediastinum and liver
or ultrasonography of the liver. In addition to this clinical
staging, information available from explorative laparotomy
was included in 30 patients. The extent of disease was
classified according to the 1987 UICC staging system using
the TNM classification (Table I). Because this staging system
is especially developed for surgically treated patients,
additionally other tumour characteristics are mentioned.
Still, there is some 'understaging' in patients who did not
undergo surgery.
Eligibility criteria included: adeno- or squamous cell
carcinoma of the oesophagus or cardiac junction when the
main part of the tumour was localised in the oesophagus,
inoperable tumours owing to infiltration into surrounding
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1996Table I TNM classification and UICC stages in oesophagal cancer
T
T
T2
T3
T4
N1
No
N,
Ml
MO
Ml
UICC staging
Stage
I
IIA
IIB
III
IV
Primary tumour
Tumour invades lamina propria or submucosa
Tumour invades muscularis propria
Tumour invades adventitia
Tumour invades adjacent structures
Regional lymph nodes
No regional lymph nodes
Regional lymph node metastases
Lymph node metastases at the coeliac axis
Distant metastases
No metastases
Haematogenous metastases
No
No
No
N,
N,
N1
AnyN
AnyN
T,
T2
T3
T,
T2
T3
T4
AnyT
tissues or distant lymph node metastases (e.g. at the coeliac
axis), or patients considered unfit for surgery; WHO
performance 2; no age limits; informed consent was
obtained in all patients. Excluded were patients with deep
ulceration or necrosis (less than 5% of all patients), and
patients with extension into the mucosa of the trachea at
bronchoscopy, because the risk of fistula formation was
deemed very high. Infiltration of the trachea at exploration
was not a contraindication.
Patients with a tumour located in the middle or lower
oesophagus were advised to take an H2-blocker or proton
pump inhibitor to reduce gastric acid secretion.
High dose rate brachytherapy (HDR)
The dummy catheter for brachytherapy was introduced by
endoscopy after intravenous sedation with 2.5-10 mg mid-
azolam, in some cases combined with 1-2 ml fentanyl plus
droperidol (Thalamonal). Administration of oxygen and
monitoring by pulse oximeter were applied routinely. The
technique was similar to that used by Hishikawa et al. (1991),
except that the patient remained in the lateral position during
the whole procedure to prevent migration of the radiation
catheter and aspiration ofsaliva. The actual procedure started
with endoscopic measurement of the tumour length with the
patient in the left lateral position; the tip ofthe endoscope was
positioned 1 cm distally to the lower margin of the tumour.
Under fluoroscopic control, this position was marked on the
skin with a lead wire. A guide wire was introduced and after
removal of the endoscope, a calibrated hollow (dummy)
catheter with a diameter of 6 mm was inserted up to the level
of the lead wire mark on the skin. When the positioning was
considered adequate under fluoroscopic control, the guide wire
was removed and the dummy catheterfixed with a mouth mask
andconnected to the Selectron afterloading system forinjection
ofthe '92Iridium radiation source into the lumen ofthecatheter.
Subsequently, the 192Iridium core was moved under computer
guidance. The target volume consisted ofvisible tumour length
plus 1 cm at the lower and upper level. The delivered dose was
calculated using a computerised radiotherapy planning system
(NPS). A radiation dose of 10 Gy calculated at 1 cm from the
source axis was administered with a high dose rate, which
implied that the dose was given in 5-10 min.
External beam radiotherapy (EBRT)
With an interval of 10-14 days after brachytherapy, the
external beam irradiation was started. EBRT was delivered
by a linear accelerator (6 or 8 MV). The dose was specified
Radiotherapy in oesophageal cancer
BG Taal et al M
1453
according to ICRU Report numbers 29 and 50. Opposed
antero-posterior and postero-anterior fields were used. The
elective fields included a 5 cm microscopically tumour-free
margin in the length of the tumour and 3 cm margins from
the width (usually 8 cm wide). A total dose of 40 Gy was
given in 20 fractions of 2.0 Gy over 4 weeks.
Evaluation
Evaluation of symptoms and signs such as dysphagia, pain
and use of medication, as well as tumour measurements were
performed 4-6 weeks after the end of radiotherapy and at
regular intervals of 6-8 weeks thereafter. Endoscopy was the
evaluation method ofchoice. In case ofpatient's refusal, only
a barium swallow was performed, combined with a CT scan,
when there was suggestion of tumour recurrence. Responses
were assessed according to WHO criteria: a complete
response (CR) defined as no macroscopic tumour; near
complete remission was defined as a residue of only a few
mm in diameter detected by endoscopy; a partial remission
(PR) occurred when at least 50% tumour reduction was
found; no change (NC) was found in case of variation within
50% regression and 25% progression of the tumour;
progressive disease was recorded when an increase of at
least 25% was present. Biopsies were not routinely taken to
document remission. The duration of response was measured
from the start of treatment until the first sign of recurrence at
endoscopy. For grading of toxicity the WHO recommenda-
tions were used. In addition, specific endoscopic patterns
were interpreted as acute radiation effect in the case of
superficial erosions with a fibrin lining and disappearance of
tumour, or chronic radiation ulceration as described by Yang
et al. (1990), including a demarcation line of ulceration and
intact opposite wall of the oesophagus.
Statistics
Survival time was calculated from the start ofradiotherapy to
the time of death or the last follow-up. Follow-up was until
date of death. Median follow-up of patients alive (n=20) at
the moment of the evaluation of the present study was 6
months (range 2-31 months).
Results
Among the 74 patients, 52 were men (70%) and a minority
of 22 (30%) women; median age was 67 years, with a wide
range of 49-91 years. Pretreatment characteristics, as
summarised in Table II, revealed an almost equal number
of squamous cell and adenocarcinomas, which can be
expected based on a localisation mostly in the distal (48
or 65%) and middle (23 or 31%) part of the oesophagus.
According to the 1987 UICC TNM staging (Table I), the
majority of patients (51 or 69%) were in an advanced stage
(III or IV). Although 23 patients were in stage II, indicating
relatively limited tumour burden, other parameters were
considered unfavourable, explaining the preference for
radiotherapy instead of surgery, e.g. poor condition (n=7),
age over 80 years (n=7) with moderate condition, a very
long (> 10 cm) tumour (n=5), or cardiopulmonary
contraindication for surgery (n =4). Explorative surgery,
usually laparotomy, performed in 30 patients, revealed
unexpected invasion into the surrounding organs (T4) in
ten patients or multiple malignant lymph nodes at the
coeliac axis, which are considered as metastatic disease (Ml)
in 20 patients.
Endoscopic dilatation within 4 weeks before the start of
radiotherapy for tumour measurement and palliation of
dysphagia was necessary in 24 patients. Treatment results in
terms ofsymptoms and signs (Table III) showed improvement
in dysphagia in 52 patients (70%). In approximately half of
these patients this symptomatic improvement was present as
early as a few days following brachytherapy. The number of6t Radiotherapy in oesophageal cancer
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Table II Pretreatment tumour characterisitcs of 74 patients with
locally advanced oesophageal cancer
Table IV Treatment results in 74 patients with locally advanced
oesophageal cancer
Male+ Female
Age, median (range) years
Pathology
Squamous cell carcinoma
Adenocarcinoma
Length
Median (range) cm
<5 cm
6-9 cm
'10 cm
Site
Proximal
Middle
Distal
UICC stage
I
II Length,> IO cm
Poor condition
Age>80 years
Cardiopulmonary
contraindications
III
IV
Explorative surgery
Local invasion
Lymph node coeliac axis
Both
Omental metastases
Dilatation needed
before radiotherapy
52 +22
67 (49-91)
36
38
7 (4-
16
51
7
3
23
48
0
5
7
7
4
21
30
30
6
18
3
3
24
17)
Objective response at endoscopy
and/or barium swallow
Complete remission
Near complete
Partial response
No change
Progressive disease
Overall response
Additional treatment of failure
Dilatation/laser
Endoprosthesis
Local recurrence
Median interval (range)
Cause of death (n =54)
From primary tumour
From distant metastases
From intercurrent disease
Total
21
12
26
10
5
59 (80%)
0
2
40
7 (2-30) months
Squa- Adeno
mous
12 9
2 10
14 12
4 6
4 1
28 (78%)l (82%)
32
21
1
Table III Symptoms and signs in 74 patients with locally advanced
oesophageal cancer
Before After
treatment treatment
Dysphagia
Normal
Almost normal
Soft food
Mashed food
Fluids only
No fluids
Dysphagia improvement
Improvement following brachytherapy
Pain
Present
Better
Similar
Worse
New symptom
Weight loss
Present
.10 kg
Weight gain
Present
Hiccup
Haemorrhage
Haematemesis
Melaena
4
8
9
18
32
3
25
11
17
9
9
2
52
29
25 22
- 12
_ 10
_ 3
_ 9
59
28
0
9
2
1
20
S
5a
Ia
aAt the time of recurrent disease: median interval 17 months (range
8 -29 months).
b
Figure 1 The barium meal in a 74-year-old woman who could
take nothing but fluids, leading to weight loss, revealed an
obstructing tumour of 6cm in length (a). Following radiotherapy
an impressive improvement in dysphagia, owing to tumour
reduction at barium meal with some stenosis (b); complete
remission was confirmed by endoscopy.
patients who could take an almost normal diet increased from
12 (16%) to 36 (49%). In only 15% of the patients dysphagia
remained a major problem as they could eat nothing but fluids,
compared with 35 patients (47%) before treatment. Along with
improvement ofdysphagia, no further weight loss occurred in
39 patients, and in five cases even some gain in weight was
assessed during the weeks ofexternal radiotherapy.
Retrosternal pain at presentation occurred either at eating
(n = 5), during obstruction (n =8), or was continuous (n = 12).
Pain improved in 12 of those 25 patients (48%), but
occasionally became more prominent (n=3). In nine other
patients pain appeared after treatment. Thus, the overall
incidence of pain remained similar.
Although most oesophageal tumours were friable and
easily bleeding at endoscopy, haematemesis and melaena were
rare conditions at presentation (3 or 4%). Also during
follow-up it was seen in only six patients (median interval 17
months), all with tumour recurrence. In four of them it was a
terminal and fatal event.Objective tumour response (Table IV), as evaluated by
endoscopy and/or barium swallow, was present in 59
patients (80%): in 21 complete (Figure 1); and 12 near
complete with only a small nodule of a few mm at
endoscopy (Figure 2); in the other 26 the criteria of partial
response with more than 50% tumour reduction were met.
In squamous cell carcinoma the overall response was not
different from adenocarcinoma (Table IV). As 20 patients
were still alive at the time of the analysis, duration of
response is not yet fully known. In the 54 patients who had
died at the time of analysis, the median duration of response
was 6 months (range 2-16 months). Additional treatment
directly following radiotherapy, in case of failure, was
required in only two cases, in whom a self-expandable
stent was inserted. Local recurrence was found in 40 patients
during follow-up investigations at regular intervals of 6
weeks according to the trial protocol; this might explain why
recurrence was usually found before dysphagia recurred. The
need for an endoprosthesis was, therefore, at a later time,
median 7-8 months.
At the time of the analysis most patients (n= 54 or 72%)
had died. As shown in the survival curve (Figure 3), the
overall median survival was 9 months (range 2-43 months).
Subgroup analysis of survival data did not show significant
differences for histological type (squamous cell vs adenocar-
cinoma), stage (I + II vs III + IV) or explorative surgery
(yes vs no). In addition, cardia carcinomas did not show a
significantly different response, although there were some
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long-term survivors. As might be expected from the incidence
of local recurrence, the cause of death was, despite the
presence of distant metastases in several cases, predominantly
related to tumour growth at the primary site in 32 out of 54
patients (59%), leading to poor general condition, pneumo-
nia, etc.
No adverse effects related to brachytherapy were found.
Side-effects (Table V) were either acute (n= 32 or 42%) at the
end of external radiotherapy, or late with a median interval
of4 months (n=20 or 27%). Acute oesophagitis, as observed
at endoscopy, was mild and short-lasting (1 -2 weeks),
leading to some retrosternal burning sensation, but without
interfering with eating and without the need for analgesics.
Delayed side-effects (> 2 months following radiotherapy)
tended to be more severe, among which fistula formation was
the most serious. This serious condition of fistula formation,
usually diagnosed at radiography, was present in six patients
with squamous cell carcinoma in the middle of the
U)
Oesophageal cancer HDR + EBRT
Overall survival
0 6 12 18 24 30 36
Time from treatment (months)
Figure 2 A tiny nodule at endoscopy as the result of impressive
tumour reduction in a 66-year-old man with adenocarcinoma of
7 cm; near complete remission after radiotherapy. Progression
with the need of an endoprosthesis after 24 months and at 31
months the patient is still alive and well.
Figure 3 The overall survival in patients with inoperable
oesophageal cancer, following an irradiation scheme of HDR
brachytherapy and EBRT. Median survival is 9 months.
Table V Side-effects of HDR brachytherapy plus external beam
irradiation in 74 patients with oesophageal cancer
None 32
Acute Mild oesophagitis 19
Delayeda Ulceration 11
Necrosis 3
Fistula 6b
Haemorrhage Radiation injury 0
Recurrent disease 5
Unknown 1
aMedian interval 4 months, range 2- 11 months. bConcurrent
tumour, either residue or recurrence, in all six patients.
Table VI Literature data on the effect of EBRT combined with brachytherapy in locally advanced oesophageal cancer
Radiotherapy Evaluation Response Death from Survival
Year Author n Brachya EBRT Brachya(Gy) scheme Subjective Objective primary tumour 5 yearb Median
1988 Hyden 46 38-50 1-3x20 NS Nearly all CR 20% 35% 0-12% 13 months
MDR PR 76%
1989 Flores 171 c 40 15 MDR Quality of life 90% NS NS 19% 11 months
1991 Petrovich 46 - 50 40 Mixed study over Good CR 20% NS 11% 8-13
23 years 48% PR 76% months
1991 Hishikawa 148 - 60 12 HDR Interval 1-3 monthsNS LCd 64% 20-37% 0-18% NS
1992 Sur 25 - 35 2x6 HDR Interval 3 months 90-70% LC 85-70% NS 1 year 78% 11
1993 Caspers 35 - 50-60 15-20 LDR Interval 6 weeks Semi-solid CR 29% 49% months
Dilatation +laser food 80% PR 71%
in severe obstruction
before EBRT
Present 10 HDR 40 Interval 6 weeks to 70% CR 28% 59% >8
series 3 months PR 51% months
aBrachytherapy: LDR, low dose rate(± 48 h perapplication); MDR, median dose rate (2 -3 h per application); HDR, high dose rate (5 - 10 min
per application). bPresented for the whole group or the variation between limited disease (stages I+II) and extensive disease (stages III +IV).
cSometimes brachytherapy before EBRT instead offollowing EBRT.dLC, local control. NS, not specified.
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oesophagus, with a median interval of 3 months (range 2-7
months). Although tumour reduction (partial remission) was
achieved in five of them, in all six cases tumour residue was
clearly present at the end of treatment. Whether fistula
formation was merely related to radiation injury or caused by
tumour residue or both remained uncertain. Ulceration or
even necrosis following irradiation, was found in 11 and 3
patients respectively. Only five of these patients (7%) needed
analgesics: four suffered from pain before radiation therapy,
which unfortunately increased during follow-up, although
partial remission was observed at endoscopy.
Discussion
Despite the large-scale availability of endoscopic diagnostic
techniques and improvement in surgical, as well as
endoscopic, treatment options, the prognosis of oesophageal
cancer is still poor, because patients are often malnourished
and presenting with locally advanced or disseminated disease.
In addition, many patients are of advanced age, and so have
limited ability to resist complications of aggressive surgery.
Hence, adequate long-term palliation by rapid relief of
dysphagia is the main goal of treatment. In patients with
metastatic disease or those in very poor condition this might
most easily be achieved by endoscopic treatment, such as
dilatation, laser coagulation, or the insertion of an
endoprosthesis (Bown, 1991). The new generation of coated
self-expandable stents are especially indicated in case of
oesophago-bronchial fistula (Taal et al., 1995a). However, for
patients with locally advanced disease, but still in fair
condition, it is widely accepted to apply radiotherapy to
achieve adequate palliation. Various schemes of irradiation
are being used. Regimens to achieve long-term palliation or
even cure are usually referred to as radical radiotherapy in
the literature, and consist of doses of 50-60 Gy delivered in
5-6 weeks. Nevertheless, figures of 5 year survival are only
6% as mentioned in the well-known review of Earlam and
Cunho-Melo (1980). Even in several other series, up to 85%
of patients still die from persistent or recurrent primary
tumour (Beatty et al., 1979; Smalley et al., 1994). Therefore,
improvement in results is greatly needed. Intraluminal
radiotherapy (brachytherapy) is not new, but recent
technical advances allowing HDR brachytherapy may offer
several advantages over the conventional technique of
external irradiation alone: better local control, reduction of
treatment time and, when given before external radiotherapy,
rapid improvement of dysphagia.
Several studies (Hyden et al., 1988; Petrovich et al., 1991;
Sur et al., 1992) claimed better local control by adding
brachytherapy to external beam radiotherapy. In the only
prospective trial available (Sur et al., 1992), a booster dose
applied by brachytherapy compared favourably with the
booster given by external application. It should be noted that
the numbers (25 patients per arm) are very small. In the other
reports (Hyden et al., 1988; Petrovich et al., 1991), being
retrospective studies over many years, the beneficial effect of
brachytherapy may be attributable to patient selection and
changes in staging procedures over the years. Staging
according to the 1987 UICC classification is very difficult in
groups of patients who are irradiated, because information
otherwise acquired by surgery, is not available. CT scan of
the mediastinum and abdomen, and even endoscopic
ultrasonography (EUS) lack accuracy for determining exact
information on depth of infiltration and lymph node
metastases (Smalley et al., 1994; Sur et al., 1992). In the
present series, there might be some understaging, especially
when patients were not particularly fit, and additional staging
procedures were limited. This might explain why, in patients
in stage II, often unfavourable aspects were found, such as a
long tumour traject and a poor condition, pointing to a more
advanced stage. However, all reported radiotherapy series
included stage II-IV. In our series only patients with locally
deep ulceration or necrosis were excluded, which was seen in
approximately 5% of all patients referred for radiotherapy,
and haematogenous metastases. Whether brachytherapy
resulted in better local control compared with conventional
schemes remains uncertain, and was not the objective of our
study. Anyway, local effect was excellent with impressive
tumour reduction in 80% and improvement in 70% of
patients. On the other hand, 59% of patients still died of the
primary site. Median survival was similar to that in the
literature (Flores et al., 1989; Hishikawa et al., 1991).
Most studies (Table VI) have applied brachytherapy as a
booster following external radiotherapy. The main problem
in oesophageal cancer, however, is dysphagia, leading to
weight loss and eventually malnutrition and poor condition.
To induce rapid tumour reduction and, hence, relief of
dysphagia, another potential advantage of brachytherapy,
this technique was applied before external radiotherapy in the
present study in contrast to most series in the literature
(Table VI). Results lived up to expectations: improvement of
dysphagia occurred within a few days in 39% ofpatients, and
at the end of the combined treatment in 70% of patients.
Further weight loss was prevented and even some weight gain
occurred during the 4 weeks of external radiotherapy. Side-
effects were acceptable. Several patients suffering from pain
before treatment improved, but in others pain appeared as a
result of radiation-induced ulceration. Overall, the incidence
of pain before and after radiotherapy was not different.
Chronic ulceration with the need for analgesics occurred in
7% of patients. Mucosal protection with sucralphate offered
little benefit to our patients with radiation ulcers, ascribed to
short duration of mucosal coating (Taal et al., 1995b).
Development of a fistula occurred only in the presence of
residual tumour and the contribution of radiotherapy to the
occurrence of a broncho-oesophageal fistula was difficult to
judge, as this is also a well-known event in the natural course
of oesophageal cancer. Haemorrhage was a serious complica-
tion and proved fatal in four of the six patients. However,
this was a terminal event caused by tumour recurrence and
not treatment related.
A third major advantage of brachytherapy is a reduction
of treatment time. A large dose of irradiation can be
delivered directly to the tumour area with limited injury to
the surrounding tissues, such as the mediastinum and lung,
because of a steep decrease of radiation dose as the distance
from the source increases. Dwell time of the intraluminal
catheter for brachytherapy varies greatly in the literature
from several days in the case of a low dose rate source
(Caspers et al., 1993; Hyden et al., 1988) to several hours
with a medium dose rate applicator (Flores et al., 1989).
Application of brachytherapy with the high dose rate source
(Hishikawa et al., 1991; Sur et al., 1992), as applied in the
present study, takes only 5-10 min, enabling the procedure
to be performed as an outpatient treatment. Another
reduction in treatment time can be achieved by a decrease
in total dose of external irradiation, when combined with
brachytherapy. For comparison, our previous treatment
schedule included 6 weeks of external irradiation only, with
a total dose of 60 Gy delivered in 30 fractions or 30 hospital
visits, similar to the radical radiotherapy schemes reported in
the literature. In the new scheme one session of brachyther-
apy was combined with 4 weeks of external irradiation (20
fractions), thus a reduction of 2 weeks (ten visits). From the
patients' point of view, upfront brachytherapy was a simple
and safe procedure: improvement of dysphagia occurred
within a few days, leading to improved quality of life and
enabling the patients to undergo external radiotherapy
without the need of dilatation procedures. A single
application of brachytherapy may be useful too in the
palliation of dysphagia, as reported in a large series by
Brewster et al. (1995). However, responses are usually of
shorter duration (4 months) compared with the combined
irradiation schemes (8-9 months). Therefore, in our institute
brachytherapy alone is especially recommended in patients
with a short life expectancy.
In conclusion, upfront HDR brachytherapy resulted inRadiotherapy in oesophageal cancer
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rapid improvement of dysphagia and, when combined with a
condensed external radiation scheme, adequate long-term
palliation was achieved in both squamous and adenocarci-
noma alike. Although local response was excellent and side-
effects acceptable, eventually patients suffered from local
recurrent disease, which was rapidly fatal in 59%. Thus, there
is still a major need for improvement of long-term results,
which might be achieved by a higher dose of external
radiotherapy, as used by Hishikawa et al. (1991), or by
combining radiotherapy with multiagent full dose chemother-
apy. A review of studies (Rich and Ajaui, 1994) reporting the
results of combined modality, showed a modest benefit
compared with radiotherapy alone, e.g. an increase in
median survival from 8 to 12 months at the cost of increased
toxicity (Herskovic et al., 1992) or some long-term survivors
(Coia et al., 1991). Another option, using a low-dose
chemotherapy scheme as radiosensitiser, might be of
benefit. Such an approach has been shown to improve local
control, and eventually survival, in non-small-cell lung cancer
(Schaake-Koning et al., 1992). Combinations of radiotherapy
schemes, including brachytherapy to induce rapid relief of
dysphagia, with chemotherapy to achieve long-term survival,
will be the subject of a future trial in the Netherlands.
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